Owkin is a French-American startup, backed by Google Ventures among others, that deploys Artificial Intelligence (AI) and Federated …
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in developing allogeneic (off-the-shelf) cellular medicines, just announced that the first …
In this post, we decided to highlight eleven entrepreneurial women, leading the way in applying advanced computational technologies, …
Personalized medicine has become a paradigm-shifting trend in healthcare - the hegemony of “one-size-fits-all” drugs is increasingly challenged by …
In The Spotlight
The Overview of AI in Drug Discovery in 2019: The “Proof-of-concept Year”
The Toxicology conference is a convergence of various streams as environmental toxicology, clinical toxicology, toxinology, regulatory toxicology, pharmacotherapeutics, drug discovery, ethnopharmacology etc aimed to carve the minds of the attendees with the advancements in every aspect of the vast and vivid fields of toxicology and pharmacology. Strengthen your global ties with the renowned researchers and internationally acclaimed toxicologists and exploit this spotlight on your excelling research.
This marcus evans industry-working group will feature many of the ongoing constraints that are faced during the formulation development of biologics and the selection and development of drug delivery systems. From protein characterisation to QbD practices and manufacturing processes, this event will enable you to grasp the latest research, learn about novel innovative delivery platforms and be part of highly interactive discussions. Experts in the field from Big Pharma companies, Research Institutes and successful Biotech companies will lead this engaging upcoming event. We will foster stimulating conversations by creating a platform to discuss high-concentrated formulations, challenges with excipient interactions, liquid and powder formulations, several delivery systems or the feasibility of oral biologics.
The Future is Now
The UK’s most forward thinking event, dedicated to exhibiting technology which is really just beginning to be introduced across hospital services, this truly is a pioneering event that will shape the future of healthcare.
Co-located with the Medical Imaging Convention and the Oncology Convention, join over 4000 medical professionals at the UK’s leading medical event for AI & Machine Learning.
This Congress has a reputation for advancing pathology practice by exploring the implementation of digital pathology and artificial intelligence to advance patient care.
40+ presentations over two days offer the opportunity to discover more about the latest advances and applications of digital pathology. Learn how artificial intelligence and machine learning is being applied to primary diagnosis and clinical research and how the image-based information environment is transforming the laboratory.
Discover the AI methods & tools set to revolutionize healthcare, pharmaceuticals, medicine & diagnostics, as well as industrial applications and key insights. Hear from industry-leading experts on the latest technological advancements and business use cases for 2020!
This Congress aim to advance pathology practice by exploring the implementation and use of digital pathology and artificial intelligence to advance patient care.
40+ presentations over two days will offer the opportunity to discover more about the latest advances and applications of digital pathology. Learn how artificial intelligence and machine learning is being applied to primary diagnosis and clinical research and how the image-based information environment is transforming the laboratory.
Pharmaceutical companies are increasingly outsourcing their R&D activities, including early-stage research programs, to third party organizations -- academic institutions, biotech startups, and private contract research organizations (CROs) -- as a means to stay competitive, flexible, and profitable against all odds.
Economically, there are factors such as increasing downward pressure on drug pricing by governments, an impending “patent cliff” threatening $198 billion worth of sales during 2019-2024), and downturns in income due to the increasing competition from generics and biosimilars.
From the innovation's point of view, there is a boom in life sciences, stimulating the emergence of novel biological targets, therapeutic modalities, and even whole new areas of drug discovery -- adding opportunities, but also complexity and uncertainty to research programs. In fact, according to Deloitte’s report, return on late-stage pipelines dropped for the top 12 pharma companies from 10.1% in 2010 down to 3.7% in 2016.
Technologically, there is an unfolding “digital revolution”, bringing even further complexity and investment cost to the table -- in a form of artificial intelligence (AI), data mining and big data technologies, data-driven diagnostics, and digital health.
Finally, the rise of the personalized medicine paradigm forces companies to rethink their research pipelines and “one-size-fits-all” product development programs, as well as reconsider their market strategies.
A transformative technology for gene editing - clustered regularly interspaced short palindromic repeats (CRISPR) -- has become ubiquitous, at least in research laboratories, where scientists efficiently adopted CRISPR technology to manipulate genes of interest. Still, applying it for humans is associated with greater risks and faces ethical issues. However, alongside a too reckless experiment of a Chinese scientist who edited babies’ genomes, plenty of companies have made well-thought progress toward transferring gene editing technologies into the clinic. Here we make a brief but pithy review on up-to-date gene editing approaches and start-up companies active in this area.
Computer-aided drug design (CADD) is a central part of so-called “rational drug design”, pioneered in the last century by companies like Vertex. Over the last decades, CADD had great influence on the way new therapeutics are discovered, however, it also showed limitations due to modest accuracy of computational tools.
The majority of software tools used for computational chemistry and biology rely on molecular mechanics -- a simplified representation of molecules, essentially reducing them down to “balls and sticks”: atoms and bonds between them. In this way it is easier to compute, but accuracy suffers greatly.
In order to gain adequate accuracy, one has to account for the electronic behavior of atoms and molecules, i.e. consider subatomic particles -- electrons and protons. This is what quantum mechanical (QM) methods are all about -- and the theory is not new, dating back to the early decades of the 20th century.
Interviews with experts
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in developing allogeneic (off-the-shelf) cellular medicines, just announced that the first COVID-19 infected patients have been dosed with remestemcel-L, the company’s proprietary allogeneic cellular medicine. This study is conducted within the framework of the 300-patient randomized placebo-controlled Phase 3 trial underway in North America which focuses on patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support.
Personalized medicine has become a paradigm-shifting trend in healthcare - the hegemony of “one-size-fits-all” drugs is increasingly challenged by novel innovative modalities and therapies, laser-sharped for a specific group of patients, or even a single patient in some cases. This is a complex story, and the progress in personalized medicine will take time and tectonic shifts in the pharmaceutical research workflow.
On the other hand, the advent of personalized medicine is only possible with a more personalized system for health assessment, new robust biomarkers, and novel approaches to run and monitor clinical trials. This will require diagnostics that can provide sufficient insight into the metabolic status of individuals, and relatively new science of metabolomics is now taking off in the biotech industry.
Canada has a firm place in the global life sciences ecosystem, being the tenth largest market for pharmaceutical sales, and home to America’s second-largest life sciences corridor. The country has a long history of life science research, including the creation of the first pacemaker and discovery of stem cells.
According to a survey conducted by BIOTECanada and Deloitte in 2018, conducted in 2018, the Canadian life sciences sector includes many early-stage companies with substantial growth potential -- 67% of responders identified themselves as being in the discovery or emerging phase of development in 2017. Surveyed organizations reported intentions to raise additional capital in the coming years and reported access to capital as the primary issue in the life sciences sector in Canada.
Editor's Pick: A Video Blog
The team at MIT created the most comprehensive database of metabolites, their interactions with proteins, protein-protein interactions, drug-protein interactions, and associations of metabolites with diseases. They then use the obtained interactions map to make inferences about the disease mechanisms and novel targets. With this new technology, the team launched a biotech startup ReviveMed in 2016 having raised $1.5M of funding so far.
“One-target-one-disease” paradigm has been around for decades, prompting numerous drug discovery programs focusing on identifying small molecules for targeting only one specific protein (or other targets) believed to be responsible for the disease mechanism.
Evaxion Biotech uses its machine learning-based platform to compare DNAs of tumor cells and DNAs healthy cells and identify mutations that are critical for the disease. This data is further used to design anticancer vaccines.
Artificial Intelligence Machine Learning Small Molecules Biopharma news In Silico Biotech Startup Pharmaceutical industry trends Big Data MedChem Interviews R&D Outsourcing Database Thought-provoking Antibiotics CROs Biologics